From the European Medicines Agency to Project Orbis: new activities and challenges to facilitate UK oncology drug approval following Brexit
Mark P. Lythgoe(Hammersmith Hospital), Richard Sullivan(Precision Spine (United States)), Mark Bower(Chelsea and Westminster Hospital), Sarah P. Blagden(Churchill Hospital), John Marriott(University of Birmingham), Jonathan Krell(Imperial College London), Ravindhi Murphy(Chelsea and Westminster Hospital NHS Foundation Trust), Ajay Aggarwal(King's College London)
Cited by 20
Related Papers
The impact of the COVID-19 pandemic on cancer deaths due to delays in diagnosis in England, UK: a national, population-based, modelling study
|The Lancet Oncology|2020|1.9k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k
Association of Prior Antibiotic Treatment With Survival and Response to Immune Checkpoint Inhibitor Therapy in Patients With Cancer
|JAMA Oncology|2019|582
The Lancet Commission on diagnostics: transforming access to diagnostics
|The Lancet|2021|442
Sustainable care for children with cancer: a Lancet Oncology Commission
|The Lancet Oncology|2020|346